SK282263B6 - Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje - Google Patents
Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje Download PDFInfo
- Publication number
- SK282263B6 SK282263B6 SK1145-95A SK114595A SK282263B6 SK 282263 B6 SK282263 B6 SK 282263B6 SK 114595 A SK114595 A SK 114595A SK 282263 B6 SK282263 B6 SK 282263B6
- Authority
- SK
- Slovakia
- Prior art keywords
- antibody
- immunoconjugate
- mab
- fragment
- chemokine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94114572 | 1994-09-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
SK114595A3 SK114595A3 (en) | 1997-03-05 |
SK282263B6 true SK282263B6 (sk) | 2001-12-03 |
Family
ID=8216289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1145-95A SK282263B6 (sk) | 1994-09-16 | 1995-09-13 | Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje |
Country Status (20)
Country | Link |
---|---|
US (1) | US5824782A (de) |
EP (1) | EP0706799B1 (de) |
JP (2) | JP3865802B2 (de) |
KR (1) | KR100386171B1 (de) |
CN (1) | CN1123185A (de) |
AT (1) | ATE208633T1 (de) |
AU (1) | AU702184B2 (de) |
CA (1) | CA2158322C (de) |
CZ (1) | CZ289641B6 (de) |
DE (1) | DE69523857T2 (de) |
DK (1) | DK0706799T3 (de) |
ES (1) | ES2167391T3 (de) |
HU (1) | HU221989B1 (de) |
NO (1) | NO315976B1 (de) |
PL (1) | PL182636B1 (de) |
PT (1) | PT706799E (de) |
RU (1) | RU2157701C2 (de) |
SK (1) | SK282263B6 (de) |
UA (1) | UA40611C2 (de) |
ZA (1) | ZA957808B (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
CN1224712C (zh) | 1997-06-04 | 2005-10-26 | 牛津生物医学(英国)有限公司 | 载体 |
ES2590912T3 (es) | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
US6562347B1 (en) | 1998-03-12 | 2003-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Chemokine-tumor antigen fusion proteins as cancer vaccines |
WO1999049866A1 (fr) * | 1998-03-31 | 1999-10-07 | Tanabe Seiyaku Co., Ltd. | Agents prophylactiques/therapeutiques contre les troubles urinaires |
MXPA00010070A (es) * | 1998-04-15 | 2004-03-10 | Lexigen Pharm Corp | Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis. |
CA2328081A1 (en) * | 1998-04-17 | 1999-10-28 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
US6869606B1 (en) | 1999-02-22 | 2005-03-22 | Millennium Pharmaceuticals, Inc. | Biotinylated-chemokine antibody complexes |
WO2000078334A1 (en) * | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
GB9915074D0 (en) * | 1999-06-28 | 1999-08-25 | Cortecs Plc | Ligand-binding composition |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
JP2003515323A (ja) * | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
US7208152B2 (en) * | 1999-11-24 | 2007-04-24 | Millennium Pharmaceuticals, Inc. | Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof |
US6319675B1 (en) | 1999-11-24 | 2001-11-20 | Millennium Pharmaceuticals, Inc. | Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
DE10019157A1 (de) * | 2000-04-18 | 2001-11-15 | Stefan Duebel | Verfahren zum Einbringen von Liganden in lebende Zellen |
JP2003533987A (ja) * | 2000-05-19 | 2003-11-18 | イス ケミカル カンパニー リミテッド | 表皮成長因子収容体に対するヒト化抗体 |
AU2001291049A1 (en) | 2000-09-15 | 2002-03-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer | Defensin-antigen fusion proteins |
WO2002022687A2 (en) | 2000-09-15 | 2002-03-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Viral chemokine-tumur antigen fusion proteins |
GB0029407D0 (en) * | 2000-12-01 | 2001-01-17 | Affitech As | Product |
PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
EP1256354A1 (de) * | 2001-05-11 | 2002-11-13 | Schering Corporation | Verfahren zur Behandlung von Krebs |
US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CZ200438A3 (cs) | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
JP4212921B2 (ja) * | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
EP1517921B1 (de) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual-specifische liganden mit erhöhter halbwertszeit |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
RS20050300A (en) | 2002-10-16 | 2007-08-03 | Euro-Celtique S.A., | Antibodies that bind cell-associated ca 125/0772p and methods of use thereof |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
MXPA05006384A (es) | 2002-12-17 | 2005-08-29 | Merck Patent Gmbh | Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2. |
AU2003290330A1 (en) * | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
EP1599572A4 (de) * | 2003-02-14 | 2007-06-13 | Univ Southern California | Zusammensetzungen und verfahren für die krebsimmuntherapie |
AU2004309050B2 (en) | 2003-12-30 | 2010-10-14 | Merck Patent Gmbh | IL-7 fusion proteins |
US8420087B2 (en) | 2004-01-05 | 2013-04-16 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
GB2424886A (en) * | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
US8053569B2 (en) * | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット |
CA2661042C (en) * | 2006-08-18 | 2012-12-11 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
CN101173008B (zh) * | 2006-11-01 | 2011-06-22 | 复旦大学 | 一种双功能融合蛋白及其制备方法和应用 |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
CA2683801A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
EP2997976A1 (de) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Verfahren und zusammensetzungen zur erhöhung der alpha-iduronidase-aktivität im zns |
MX349306B (es) | 2007-09-21 | 2017-07-19 | Univ California | Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales. |
WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
CA2748889A1 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
KR20120030383A (ko) | 2009-04-22 | 2012-03-28 | 메르크 파텐트 게엠베하 | 변형된 FcRn 결합 자리를 갖는 항체 융합 단백질 |
HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
EP2983701A2 (de) | 2013-03-11 | 2016-02-17 | Genzyme Corporation | Ortsspezifische antikörper-arzneimittel-konjugation durch glycoengineering |
EP3677591B1 (de) | 2013-04-29 | 2022-12-28 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38-antikörper und fusionen davon mit abgeschwächtem interferon-alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
PL3129067T3 (pl) | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
MX2017004664A (es) | 2014-10-09 | 2017-06-30 | Genzyme Corp | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. |
MX2017005481A (es) | 2014-10-29 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd | Variantes de interferon a2b. |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
CN110087673A (zh) | 2016-07-19 | 2019-08-02 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
KR20200036945A (ko) * | 2017-09-29 | 2020-04-07 | 난트셀, 인크. | 항원성 단백질 및 이를 위한 방법(antigenic proteins and methods therefor) |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
DE69127749T2 (de) * | 1990-03-20 | 1998-04-16 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
DK0574395T3 (da) * | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
AU665360B2 (en) * | 1991-07-05 | 1996-01-04 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
ES2144440T3 (es) * | 1992-08-18 | 2000-06-16 | Centro Inmunologia Molecular | Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen. |
-
1995
- 1995-09-06 DE DE69523857T patent/DE69523857T2/de not_active Expired - Fee Related
- 1995-09-06 AT AT95113956T patent/ATE208633T1/de not_active IP Right Cessation
- 1995-09-06 PT PT95113956T patent/PT706799E/pt unknown
- 1995-09-06 EP EP95113956A patent/EP0706799B1/de not_active Expired - Lifetime
- 1995-09-06 ES ES95113956T patent/ES2167391T3/es not_active Expired - Lifetime
- 1995-09-06 DK DK95113956T patent/DK0706799T3/da active
- 1995-09-08 AU AU30533/95A patent/AU702184B2/en not_active Ceased
- 1995-09-11 JP JP23283295A patent/JP3865802B2/ja not_active Expired - Fee Related
- 1995-09-13 SK SK1145-95A patent/SK282263B6/sk unknown
- 1995-09-14 CA CA002158322A patent/CA2158322C/en not_active Expired - Fee Related
- 1995-09-14 CN CN95116279A patent/CN1123185A/zh active Pending
- 1995-09-14 UA UA95094164A patent/UA40611C2/uk unknown
- 1995-09-14 CZ CZ19952375A patent/CZ289641B6/cs not_active IP Right Cessation
- 1995-09-15 US US08/528,523 patent/US5824782A/en not_active Expired - Fee Related
- 1995-09-15 HU HU9502711A patent/HU221989B1/hu not_active IP Right Cessation
- 1995-09-15 NO NO19953650A patent/NO315976B1/no not_active IP Right Cessation
- 1995-09-15 ZA ZA957808A patent/ZA957808B/xx unknown
- 1995-09-15 KR KR1019950030385A patent/KR100386171B1/ko not_active IP Right Cessation
- 1995-09-15 RU RU95115976/14A patent/RU2157701C2/ru not_active IP Right Cessation
- 1995-09-15 PL PL95310493A patent/PL182636B1/pl not_active IP Right Cessation
-
2005
- 2005-11-17 JP JP2005332965A patent/JP2006117684A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0706799A3 (de) | 1996-12-04 |
CA2158322A1 (en) | 1996-03-17 |
DE69523857D1 (de) | 2001-12-20 |
ATE208633T1 (de) | 2001-11-15 |
JPH0899901A (ja) | 1996-04-16 |
UA40611C2 (uk) | 2001-08-15 |
PL182636B1 (pl) | 2002-02-28 |
CZ237595A3 (en) | 1996-04-17 |
HUT75836A (en) | 1997-05-28 |
KR100386171B1 (ko) | 2003-08-21 |
SK114595A3 (en) | 1997-03-05 |
CZ289641B6 (cs) | 2002-03-13 |
CA2158322C (en) | 2009-06-16 |
AU702184B2 (en) | 1999-02-18 |
JP3865802B2 (ja) | 2007-01-10 |
PL310493A1 (en) | 1996-03-18 |
NO953650L (no) | 1996-03-18 |
PT706799E (pt) | 2002-05-31 |
CN1123185A (zh) | 1996-05-29 |
KR960010023A (ko) | 1996-04-20 |
DK0706799T3 (da) | 2002-02-25 |
RU2157701C2 (ru) | 2000-10-20 |
JP2006117684A (ja) | 2006-05-11 |
HU221989B1 (hu) | 2003-03-28 |
DE69523857T2 (de) | 2002-06-13 |
HU9502711D0 (en) | 1995-11-28 |
ES2167391T3 (es) | 2002-05-16 |
ZA957808B (en) | 1996-05-07 |
NO953650D0 (no) | 1995-09-15 |
NO315976B1 (no) | 2003-11-24 |
EP0706799A2 (de) | 1996-04-17 |
AU3053395A (en) | 1996-03-28 |
EP0706799B1 (de) | 2001-11-14 |
US5824782A (en) | 1998-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK282263B6 (sk) | Imunokonjugát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje | |
RU2129018C1 (ru) | Иммуноконьюгат, способ получения иммуноконьюгата и фармацевтическая композиция | |
CA2095836C (en) | Cytokine immunoconjugates | |
US5650150A (en) | Recombinant antibody cytokine fusion proteins | |
AU2001275246B2 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
WO1995009917A1 (en) | Genetically engineered bispecific tetravalent antibodies | |
KR20010022075A (ko) | T세포활성화를유도하는슈퍼항원접합체에의한표적세포의세포용해 | |
IE63186B1 (en) | Cloned genes encoding IG-CD4 fusion proteins and the use thereof | |
US20100015661A1 (en) | Antibody-rnase-conjugate | |
CA2318284A1 (en) | Antibody/receptor targeting moiety for enhanced delivery of armed ligand | |
CA2294223C (en) | Anti-cd40l immunotoxins for the treatment of diseases | |
Burbage et al. | Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells | |
Sun et al. | Antitumour activity of a chimeric antibody against the leucocyte antigen CD48 |